Fig. 1: Preparation and characterization of ALK1510-c4 DTP cells from ALK1510-c4 cells. | npj Precision Oncology

Fig. 1: Preparation and characterization of ALK1510-c4 DTP cells from ALK1510-c4 cells.

From: Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer

Fig. 1

a ALK1510-c4 DTP cells were generated from ALK1510-c4 cells after treatment with 1000 nM alectinib for 9 days, ALK1510-c4 regrown cells were generated from ALK1510-c4 DTP cells cultured in alectinib-free cell culture for 37 days, and comparison with ALK1510-c4 cell controls were assessed in a cell proliferation assay (mean [SD] of n = 3 experiments, *P < 0.05 between ALK1510-c4 and ALK1510-c4 DTP and ALK1510-c4 regrown; Tukey’s HSD test). b Immunoblots of cell lysates showing changes in phosphorylated and/or total ALK, AKT, ERK, STAT3, and cleaved PARP in ALK1510-c4 cells treated with 1000 nM alectinib for 1, 3, 24, and 48 h and 9 days. c Immunoblots of cell lysates showing changes in BIM, stem cell marker CD133, vimentin, and E-cadherin protein levels in ALK1510-c4 cells and ALK1510-c4 DTP cells. d Immunoblots of cell lysates showing change in phosphorylated and/or total ALK, AKT, ERK and STAT3 protein levels in ALK1510-c4 cells and ALK1510-c4 DTP cells after treatment with 1000 nM alectinib for 1 h. Microscopic examination of ALK1510-c4 parental and DTP cells generated from ALK1510-c4 by treatment with 1000 nM alectinib for 9 days with phase contrast (e), and crystal violet staining (f). g Immunoblots of cell lysates in ALK1510-c4 DTP cells after 13 and 26 days culture in the alectinib-free medium.

Back to article page